Endoscopic debulking resection with additive chemoradiotherapy:Optimal management of advanced inoperable esophageal squamous cell carcinoma

doi:10.4251/wjgo.v14.i9.1758

科研成果详情

题名	Endoscopic debulking resection with additive chemoradiotherapy:Optimal management of advanced inoperable esophageal squamous cell carcinoma
作者	Ren, Li-Hua 1; Zhu, Ye 1; Chen, Rong 2; Sachin, Mulmi Shrestha 3; Lu, Qin 1; Xie, Wei-Hua4; Lu, Tong 5; Wei, Xiao-Ying 6; Shi, Rui-Hua 1
发表日期	2022-09-15
发表期刊	World Journal of Gastrointestinal Oncology 影响因子和分区
语种	英语
原始文献类型	Article
关键词	Esophageal squamous cell carcinoma Endoscopic resection Chemoradiotherapy Overall survival Progression-free survival
其他关键词	DEFINITIVE CHEMORADIOTHERAPY ; SUBMUCOSAL DISSECTION ; MUCOSAL RESECTION ; RISK-FACTORS ; PHASE I/II ; CANCER ; CHEMOTHERAPY ; RECURRENCE ; SURGERY ; RADIOTHERAPY
摘要	BACKGROUND There is no remedial strategy other than definitive chemoradiotherapy for patients with advanced esophageal squamous cell carcinoma(ESCC) who are not eligible to undergo surgical treatment.AIM To introduce a novel therapy called endoscopic debulking resection(Ed R) followed by additive chemoradiotherapy(CRT) and evaluate its efficacy and safety.METHODS Advanced, inoperable ESCC patients between 1 January 2015 and 30 December 2019 were investigated retrospectively. Patients who received Ed R followed by CRT were deemed the Ed R + CRT group and those without CRT were deemed the Ed R group. Overall survival(OS), progression-free survival(PFS), and adverse events were evaluated.RESULTS A total of 41 patients were enrolled. At a median follow-up of 36 mo(range: 1-83), the estimated 1-, 2-, and 3-year cumulative OS rates of patients who underwent Ed R plus additive CRT were 92.6%, 85.2%, and 79.5%, respectively, which were higher than those of patients who underwent Ed R alone(1-year OS, 83.3%; 2-year OS, 58.3%; 3-year OS, 50%; P = 0.05). The estimated 2-year cumulative PFS rate after Ed R + CRT was 85.7%, while it was 61.5% after Ed R(P = 0.043). According to the univariate and multivariate Cox regression analyses, early clinical stage(stage ≤ IIB) and additive CRT were potential protective factors for cumulative OS. No severe adverse events were observed during the Ed R procedure, and only mild to moderate myelosuppression and radiation pneumonia were observed in patients who underwent additive CRT after Ed R.CONCLUSION Ed R plus CRT is an alternative strategy for selective advanced inoperable ESCC patients.
资助项目	Supported by Fundamental Research Funds for the Central Universities;; Postgraduate Research and Practice Innovation Program of Jiangsu Province,No. KYCX19＿0118;; Jiangsu Science and Technology Project;; Innovative Team Project of Esophagus,No. 2017ZXK7QW08;; National Natural Science Foundation of China,No. 81570503
出版者	BAISHIDENG PUBLISHING GROUP INC
出版地	PLEASANTON
ISSN	1948-5204
卷号	14 期号:09 页码:1758-1770
DOI	10.4251/wjgo.v14.i9.1758
页数	13
WOS类目	Oncology ; Gastroenterology & Hepatology
WOS研究方向	Oncology ; Gastroenterology & Hepatology
WOS记录号	WOS:000862388900012
收录类别	CNKI ; SCOPUS ; SCIE ; PUBMED
URL	查看原文
PubMed ID	36187386
SCOPUSEID	2-s2.0-85138111722
通讯作者地址	[Shi, Rui-Hua]Department of Gastroenterology,Zhongda Hospital,School of Medicine,Southeast University,Jiangsu Province,Nanjing,210009,China
Scopus学科分类	Oncology;Gastroenterology
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/167719
专题	第二临床医学院，附属第二医院、育英儿童医院附属第二医院
通讯作者	Shi, Rui-Hua
作者单位	1.Department of Gastroenterology,Zhongda Hospital,School of Medicine,Southeast University,Jiangsu Province,Nanjing,210009,China; 2.Department of Oncology,Zhongda Hospital,School of Medicine,Southeast University,Jiangsu Province,Nanjing,210009,China; 3.Department of Gastroenterology,Affiliated Zhongda Hospital of Southeast University,Jiangsu Province,Nanjing,210009,China; 4.Quality Management,The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University,Zhejiang Province,Wenzhou,325000,China; 5.Department of Radiology,Zhongda Hospital,Southeast University,Jiangsu Province,Nanjing,210009,China; 6.Department of Pathology,Zhongda Hospital,Southeast University,Jiangsu Province,Nanjing,210009,China
推荐引用方式 GB/T 7714	Ren, Li-Hua,Zhu, Ye,Chen, Rong,et al. Endoscopic debulking resection with additive chemoradiotherapy:Optimal management of advanced inoperable esophageal squamous cell carcinoma[J]. World Journal of Gastrointestinal Oncology,2022,14(09):1758-1770.
APA	Ren, Li-Hua., Zhu, Ye., Chen, Rong., Sachin, Mulmi Shrestha., Lu, Qin., ... & Shi, Rui-Hua. (2022). Endoscopic debulking resection with additive chemoradiotherapy:Optimal management of advanced inoperable esophageal squamous cell carcinoma. World Journal of Gastrointestinal Oncology, 14(09), 1758-1770.
MLA	Ren, Li-Hua,et al."Endoscopic debulking resection with additive chemoradiotherapy:Optimal management of advanced inoperable esophageal squamous cell carcinoma".World Journal of Gastrointestinal Oncology 14.09(2022):1758-1770.